Drugs / PEGylated Liposome
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04592692 | Dec 2019 → Feb 2022 | hemophilia A | Ascension Healthcare Development Limited | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGylated Liposome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04592692 ↗ |
| Known as | PEGLip | “PEGylated Liposome (PEGLip)” NCT04592692 ↗ |
| Route | Intravenous | “Intravenous co-administration of PEGLip with Simoctocog alfa” NCT04592692 ↗ |